down arrow

OncoTherapy Science, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3202150003
JPY
22.00
0.00 (0.00%)

Mar 27

TKS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Cyfuse Biomedical KK
Peptidream, Inc.
SUSMED, Inc.
Chiome Bioscience, Inc.
StemCell Institute
OncoTherapy Science, Inc.
GNI Group Ltd.
Oncolys BioPharma, Inc.
Carna Biosciences, Inc.
MEDINET Co., Ltd.
Stella Pharma Corp.

Why is OncoTherapy Science, Inc. ?

1
Poor Management Efficiency with a low ROE of 0%
  • The company has reported losses. Due to this company has reported negative ROE
  • INTEREST(HY) At JPY 0.66 MM has Grown at 19.93%
  • RAW MATERIAL COST(Y) Grown by 172.84% (YoY)
  • DEBTORS TURNOVER RATIO(HY) Lowest at 8.72 times
2
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -25.00%, its profits have risen by 28.7%
3
Underperformed the market in the last 1 year
  • Even though the market (Japan Nikkei 225) has generated returns of 38.30% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -25.00% returns
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is OncoTherapy Science, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
OncoTherapy Science, Inc.
-100.0%
-0.13
68.36%
Japan Nikkei 225
40.96%
1.35
28.28%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
18.86%
EBIT Growth (5y)
10.23%
EBIT to Interest (avg)
-1,319.44
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.07
Sales to Capital Employed (avg)
0.89
Tax Ratio
0.27%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.57
EV to EBIT
-6.70
EV to EBITDA
-6.70
EV to Capital Employed
-101.76
EV to Sales
7.29
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-112.08%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company
NET PROFIT(HY)

Higher at JPY -407.56 MM

ROCE(HY)

Highest at -59.42%

INVENTORY TURNOVER RATIO(HY)

Highest at 8.38 times

-17What is not working for the Company
INTEREST(HY)

At JPY 0.66 MM has Grown at 19.93%

RAW MATERIAL COST(Y)

Grown by 172.84% (YoY

DEBTORS TURNOVER RATIO(HY)

Lowest at 8.72 times

NET SALES(Q)

Lowest at JPY 165.6 MM

PRE-TAX PROFIT(Q)

Fallen at -32.56%

Here's what is working for OncoTherapy Science, Inc.

Net Profit
Higher at JPY -407.56 MM
than preceding 12 month period ended Dec 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (JPY MM)

Inventory Turnover Ratio
Highest at 8.38 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Here's what is not working for OncoTherapy Science, Inc.

Net Sales
At JPY 165.6 MM has Fallen at -51.04%
Year on Year (YoY)
MOJO Watch
Near term sales trend is extremely negative

Net Sales (JPY MM)

Interest
At JPY 0.66 MM has Grown at 19.93%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Net Sales
Lowest at JPY 165.6 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (JPY MM)

Pre-Tax Profit
Fallen at -32.56%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (JPY MM)

Debtors Turnover Ratio
Lowest at 8.72 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost
Grown by 172.84% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Download on App Store
Get it on Google Play
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."